Business
Companion Diagnostic Supply Agreement with SGSC
Companion Diagnostic Supply Agreement with SGSC.
About this update from Cizzle Biotechnology Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8733P\n Cizzle Biotechnology Holdings PLC\n 22 October 2021\n \n \n \n 22 October 2021\n Cizzle Biotechnology Holdings Plc\n (\"Cizzle Biotechnology\" or the \"Company\")\n \n \n Companion Diagnostic Supply Agreement with St George Street Capital\n \n \n Research and Development agreement worth up to £1 million signed for potential autoimmune disease testing and possible additional companion diagnostics\n \n Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce it has executed a research and development agreement to develop a companion diagnostic test for autoimmune disease with St George Street Capital (\"SGSC\"), the UK-based biomedical charity. The new diagnostic platform will be used to develop tests that will operate alongside SGSC's programme for the development of therapeutic assets licensed to SGSC from one of the world's largest pharmaceutical companies, Astra Zeneca. This seeks to address unmet clinical needs in a wide variety of autoimmune diseases which will significantly broaden the Company's product pipeline and for which SGSC will pay Cizzle Biotechnology up to £1 million in development fees.\n \n As announced on 20 September 2021, Cizzle Biotechnology signed an agreement with SGSC to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street's therapeutic asset AZD1656 of up to £5 million. This followed SGSC's announcement on 9 September 2021 of encouraging clinical trial results arising from their existing collaboration with AstraZeneca and funded by international investment through Excalibur Medicines Ltd and an HM Government grant through the UKRI/Innovate UK programme. \n \n \n \n \n This new commercial contract with SGSC will seek to provide valuable diagnostic information on patients based on the proposed mechanism of action of AZD1656 which may be linked to the regulation of inflammation through activating migration of T regulatory cells to sites of damaging inflammation. Migration of T regulatory cells amplify the body's own mechanism of damping down an inappropriate inflammatory overreaction and hence may have important clinical benefits in managing autoimmune disease.\n \n Under the commercial contract entered into, the parties will collaborate closely in t...